This new handpiece from BIOLASE uses proprietary technology from the Waterlase iPlus platform to create a comfortable and thorough innovation for skin resurfacing.
Dental laser group BIOLASE has announced the launch of its newest innovation, the Waterlase Fractional Handpiece. This United States Food and Drug Administration-cleared skin resurfacing handpiece is said to deliver ablative and non-ablative fractional treatments, providing the doctor with control over penetration depth with different treatment parameters and techniques, according to a press release from BIOLASE. It creates a uniform patter of micro-perforations on tissue surface while simultaneously offering patients faster healing and recovery time.
It is formulated from the same technology as the Waterlase iPlus platform, which is proven in the market, according to BIOLASE President and Chief Executive Officer John Beaver.
“We’re very pleased to announce the launch of this state-of-the-art handpiece in the United States, which works with our current Waterlase iPlus platform to deliver faster and more efficient skin resurfacing,” Beaver says in the press release. “I believe this launch will further accelerate the adoption of our Waterlase technology in the dental industry and is consistent with our commitment to provide less invasive, patient-friendly technology for both patients and clinicians and expands our access to the approximately $215 million skin resurfacing market worldwide.”
The Waterlase Fractional Handpiece uses BIOLASE’s proprietary water spray, meaning that no local or topical anesthetic is necessary for a variety of procedures. It is also designed to be ergonomic, offering comfort for clinicians using the handpiece frequently.